LeadershipThe new CEO, John Shannon, outlined a 3-pronged approach for Xeris' future, focusing on maintaining rapid commercial growth, renewed commitment to financial discipline, and improving external communication to better set expectations for product growth and value creation.
Product DevelopmentXeris announced positive topline Phase 2 results for its once-weekly subcutaneous levothyroxine injection candidate utilizing its proprietary XeriSol platform technology.
Revenue GrowthGvoke revenues grew approximately 20% quarter-over-quarter and approximately 28% year-over-year, with market share reaching around 34%, primarily bolstered by new starts and increased awareness of the need for rescue glucagon products.